

Paulo Roberto Abro Ferreira

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9507116/paulo-roberto-abrao-ferreira-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

20
papers

151
citations

6
h-index

11
g-index

21
ext. papers

190
ext. citations

3.3
avg, IF

2.24
L-index

#	Paper	IF	Citations
20	Baseline factors associated with death in a COVID-19 hospital cohort, Sao Paulo, 2020. <i>Revista De Saude Publica</i> , 2021 , 55, 76	2.4	
19	Acute kidney injury: Incidence, risk factors, and outcomes in severe COVID-19 patients. <i>PLoS ONE</i> , 2021 , 16, e0251048	3.7	8
18	Impact of In-Hospital infection with SARS-CoV-2 among Inpatients at a university hospital. <i>American Journal of Infection Control</i> , 2021 , 49, 1464-1468	3.8	0
17	The interference of COVID-19 in the male reproductive system: Important questions and the future of assisted reproduction techniques. <i>Clinics</i> , 2020 , 75, e2183	2.3	3
16	Pre-exposure prophylaxis during the SARS-CoV-2 pandemic: can PrEP prevent COVID-19-related symptoms?. <i>Epidemiology and Infection</i> , 2020 , 148, e231	4.3	4
15	Hepatitis B viremia in HIV-coinfected individuals under antiretroviral therapy. <i>Brazilian Journal of Infectious Diseases</i> , 2019 , 23, 441-450	2.8	1
14	Disease burden of chronic hepatitis C in Brazil. <i>Brazilian Journal of Infectious Diseases</i> , 2015 , 19, 363-8	2.8	15
13	The clinical effectiveness of pegylated interferon and ribavirin for the treatment of chronic hepatitis C in HIV-infected patients in Brazil: a multicentric study. <i>Brazilian Journal of Infectious Diseases</i> , 2015 , 19, 15-22	2.8	1
12	Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis. <i>PLoS ONE</i> , 2015 , 10, e0138503	3.7	3
11	Characteristics of an outpatient chronic hepatitis B virus infection cohort. <i>Einstein (Sao Paulo, Brazil)</i> , 2015 , 13, 189-95	1.2	2
10	Predictive value of FIB-4 and APRI versus METAVIR on sustained virologic response in genotype 1 hepatitis C patients. <i>Hepatology International</i> , 2014 , 8, 83-93	8.8	6
9	Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access program. <i>Journal of Hepatology</i> , 2014 , 61, 976-83	13.4	20
8	Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study. <i>Brazilian Journal of Infectious Diseases</i> , 2014 , 18, 48-52	2.8	11
7	Detection of lamivudine-resistant variants and mutations related to reduced antigenicity of HBsAg in individuals from the cities of Santos and São Paulo, Brazil. <i>Virology Journal</i> , 2013 , 10, 320	6.1	10
6	Association between IL28B gene polymorphisms and sustained virological response in patients coinfecting with HCV and HIV in Brazil. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 509-10	5.1	6
5	Short communication: Evaluation of GB virus C/hepatitis G viral load among HIV type 1-coinfecting patients in São Paulo, Brazil. <i>AIDS Research and Human Retroviruses</i> , 2012 , 28, 1301-4	1.6	4
4	Full-length genomic sequence of hepatitis B virus genotype C2 isolated from a native Brazilian patient. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2011 , 106, 495-8	2.6	4

3	Imbalance between endothelial progenitors cells and microparticles in HIV-infected patients naive for antiretroviral therapy. <i>Aids</i> , 2011 , 25, 1595-601	3.5	4 ¹
2	Response predictors to treatment with pegylated interferon in chronic hepatitis B. <i>Brazilian Journal of Infectious Diseases</i> , 2010 , 14, 519-25	2.8	6
1	Response predictors to treatment with pegylated interferon in chronic hepatitis B. <i>Brazilian Journal of Infectious Diseases</i> , 2010 , 14, 519-525	2.8	